` LPTX (Leap Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

LPTX
vs
S&P 500

Over the past 12 months, LPTX has underperformed S&P 500, delivering a return of -29% compared to the S&P 500's +14% growth.

Stocks Performance
LPTX vs S&P 500

Loading
LPTX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LPTX vs S&P 500

Loading
LPTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
LPTX vs S&P 500

Loading
LPTX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Leap Therapeutics Inc vs Peers

S&P 500
LPTX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Leap Therapeutics Inc
Glance View

Market Cap
116.1m USD
Industry
Biotechnology

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.

LPTX Intrinsic Value
Not Available
Back to Top